A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - A Randomized Trial (DESTINATION 2)
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
研究联系人备份
- 姓名:Zachary Moore, MD, PhD
- 电话号码:212-639-5803
- 邮箱:MooreZ@mskcc.org
学习地点
-
-
New Jersey
-
Basking Ridge、New Jersey、美国、07920
- 招聘中
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
Middletown、New Jersey、美国、07748
- 招聘中
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
Montvale、New Jersey、美国、07645
- 招聘中
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
-
New York
-
Commack、New York、美国、11725
- 招聘中
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
Harrison、New York、美国、10604
- 招聘中
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
-
Uniondale、New York、美国、11553
- 招聘中
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
-
接触:
- Victoria Brennan, MBBCH BAO
- 电话号码:212-639-8904
- 邮箱:brennanv@mskcc.org
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
Documentation of Disease
o Patients must have pathologically confirmed prostate adenocarcinoma.
Definition of Disease
- Grade Group (GG) 1, 2, or 3.
- PSA less than 20 ng/mL prior to starting ADT, if used.
- Clinical stage of TX, T1 or T2 on digital rectal examination. May have up to radiological stage T3a on MRI. MRI must be performed within 12 months of randomization.
- MRI-visible tumor(s), all having PIRADS v2.1 scores of 3, 4, or 5. Each tumor should be able to be delineated on T2 and diffusion-weighted imaging (DWI) +/- dynamic contrast-enhanced imaging (DCE).
- Tumor nodule visible on MRI should be considered able to be boosted by treating clinician (ie meet urethral constraints while maintaining mandatory GTV coverage) and <2.5cm in maximal dimension.
- The MRI-defined lesion must be confirmed as malignant on biopsies (Grade group 1, 2, or 3).
- Patients can be concurrently treated with androgen deprivation therapy (ADT) if this would be standard of care. LHRH analogues, LHRH agonists or Bicalutamide are permitted. ADT is not mandatory where this would usually be omitted. Patients needing greater than 6 months of ADT due to disease parameters should be excluded.
- No high grade disease (GG3) occult to MRI-defined lesion. As a guide, any pathology for which you would consider surveillance (e.g. GG1, low volume GG2) is allowed outside of the MRI-defined area.
- No contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia).
- Prostate volume less than or equal to 90mL.
- No evidence of nodal or distant metastatic disease.
Prior Treatment
o No history of previous radiation to the prostate, prostate surgery (including transurethral resection of the prostate (TURP)), or other local prostate cancer treatments.
- Age ≥ 18
- ECOG Performance Status of ≤ 2 (See Appendix I for performance status criteria)
Required Organ Function
Adequate hematologic function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
- Platelets ≥ 100,000 cells/mm3
- Hemoglobin ≥ 8 g/dl
Adequate renal function defined as follows:
- Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula:
CrCl (mL/min) = [140 - age (years)] x weight (kg) / 72 x creatinine (mg / dL) {x 0.85 for female patients}
Adequate hepatic function defined as follows:
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
- AST and ALT ≤3 x institutional ULN
Adequate cardiac function defined as follows:
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
To be eligible for this trial, patients should be class 2B or better (see Appendix II: New York Heart Association (NYHA) Functional Classification).
- Comorbid Conditions
- No active infection requiring parenteral antibiotic(s).
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- No severe GU symptoms that would preclude extreme hypofractionation per the discretion of the treating physician.
- No IPSS Score greater than 19.
No comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up.
- Ability of the participant to understand and the willingness to sign a written informed consent form.
- Willing to consent to contraception during and for 1 year after treatment when applicable.
- Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Group 1: Uniform dose SBRT
|
MR-guided 2 fraction Stereotactic Body Radiation Therapy
其他名称:
|
|
实验性的:Group 2: De-escalated dose SBRT
|
MR-guided 2 fraction Stereotactic Body Radiation Therapy
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with acute GU toxicities
大体时间:12 weeks from the start of radiation therapy
|
To estimate the absolute and relative risk of acute GU toxicity (CTCAE v5) when delivering dose de-escalated or uniform dose prostate SBRT, both using a 2-fraction regimen.
|
12 weeks from the start of radiation therapy
|
合作者和调查者
调查人员
- 首席研究员:Victoria Brennan, MBBCH BAO、Memorial Sloan Kettering Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 26-150
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.